Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
about
The restorative role of annexin A1 at the blood-brain barrier.A role for endogenous histamine in interleukin-8-induced neutrophil infiltration into mouse air-pouch: investigation of the modulatory action of systemic and local dexamethasoneInhibitory effect of peptides derived from the N-terminus of lipocortin 1 on arachidonic acid release and proliferation in the A549 cell line: identification of E-Q-E-Y-V as a crucial component.Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1.Dexamethasone enhances interaction of endogenous annexin 1 with L-selectin and triggers shedding of L-selectin in the monocytic cell line U-937.Annexin 1: a paracrine/juxtacrine mediator of glucorticoid action in the neuroendocrine system.Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes.Reduction of nitric oxide release from alveolar macrophages by a lipocortin peptide.Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.Annexin A1 and the regulation of innate and adaptive immunity.Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling.The role of lipocortin-1 in dexamethasone-induced suppression of PGE2 and TNF alpha release from human peripheral blood mononuclear cells.Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site.Kinase-dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptides.Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2.Annexin A1 modulates macula densa function by inhibiting cyclooxygenase 2.An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease.
P2860
Q27687514-C0C09A3A-22B0-414F-AF89-A14E868B6F06Q28367596-83460D7C-BF2A-412F-BD91-B1CE39FF5B5BQ32071132-EE76DE5F-1059-4597-88A7-EA5A307B652FQ33922787-6490F486-8DF1-49A8-9D06-80C59A0EE8C8Q35045668-0223FF8F-A55C-48FF-82A8-D1A608E681DBQ35196685-C10560CD-1B71-433C-827D-99ADE9A1A840Q35609675-499231B0-87BA-416E-B21E-FE8EA03F2D03Q35609825-3A524C41-0688-40EA-9A84-8A968D1E09A0Q36298336-A5E58439-E053-4BF3-9EC0-94D07E66728BQ36449551-BDA97A86-55FF-440A-8A79-A735B585A648Q36882549-FE173C2E-F729-4A7F-8EB5-FA4D44F54A40Q37618896-3C9A67ED-CD27-4AE8-B46E-28B7C8ED0EAAQ37642476-653BEB69-9B78-425C-A47D-464F923FCD3FQ41834792-4DB5E120-DBF5-4B1C-8C8D-79DA320880A4Q41862109-5FB18D7D-4566-41B9-A3CF-5233BB067711Q43559647-C9CD6C70-67BC-41AD-8452-B415EA6095C9Q44581735-DEE2C6FA-F87B-442A-AC2D-CABF7CCB94C5Q46199638-459F3A34-683B-42F0-932A-9417EC2801E2Q47389333-1634176E-3D18-48D9-A991-4A392E2569C4Q50888630-E51F495C-B03C-4A0A-A276-26470BFB3CFA
P2860
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@en
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@nl
type
label
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@en
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@nl
prefLabel
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@en
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@nl
P2093
P2860
P1476
Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1993.TB12843.X
P407
P577
1993-03-01T00:00:00Z